STERIS (STE) Set to Post Quarterly Earnings on Wednesday

STERIS (NYSE:STE) will likely be issuing its Q2 2027 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $2.67 per share and revenue of $1.56 billion for the quarter. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Individuals may visit the company’s upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, topping the consensus estimate of $2.49 by $0.10. The business had revenue of $1.49 billion for the quarter, compared to analyst estimates of $1.49 billion. STERIS had a net margin of 13.34% and a return on equity of 14.34%. STERIS’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.34 earnings per share. On average, analysts expect STERIS to post $11.17 EPS for the current fiscal year and $12.40 EPS for the next fiscal year.

STERIS Price Performance

Shares of STE opened at $227.07 on Monday. The stock has a market cap of $22.14 billion, a PE ratio of 27.76 and a beta of 0.86. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.35 and a current ratio of 1.91. STERIS has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The firm’s 50-day simple moving average is $219.81 and its two-hundred day simple moving average is $225.20.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Tuesday, November 17th will be given a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, November 17th. STERIS’s payout ratio is currently 33.74%.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of STERIS in a research note on Monday, August 24th. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 11th. UBS Group dropped their target price on STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $275.00 target price (up from $270.00) on shares of STERIS in a research note on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $271.33.

Insider Activity

In other news, Director Mohsen Sohi sold 4,058 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total transaction of $956,795.24. Following the sale, the director owned 24,305 shares in the company, valued at $5,730,632.90. This represents a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.12% of the company’s stock.

STERIS Company Profile

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, procedural care and the safe manufacture of healthcare and life sciences products. Its offerings include surgical equipment and operating-room solutions, sterilization and decontamination systems, endoscopy products, cleaning and disinfection technologies, and related consumable products.

The company also provides outsourced sterilization and laboratory services through its Applied Sterilization Technologies business.